---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-217484"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-09-25T23:59:59+00:00"
generated_at: "2026-05-17T05:40:11.541042+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia reports nex-z Phase 1 data: 92% mean TTR reduction at 24 months, 72% of patients show mNIS+7 improvement

## Summary
- Mean serum TTR reduction of 92% at 24 months (n=33) and 90% at 36 months (n=12) after single dose.
- 72% of evaluable patients (13/18) achieved ≥4-point improvement in mNIS+7 by month 24; most who had progressed on patisiran improved.
- 89% of all 36 patients showed improvement or stability in PND scores through 24 months; mBMI, QoL-DN, NfL all trended toward improvement.
- Nex-z generally well tolerated; infusion-related reactions mild/moderate, no discontinuations; three Grade ≥3 liver enzyme elevations resolved spontaneously.
- Phase 3 MAGNITUDE-2 enrollment (approx. 50 patients) expected to complete in H1 2026; BLA submission for ATTRv-PN targeted by 2028.

## SEC filing metadata
- accession: 0001193125-25-217484
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312525217484/0001193125-25-217484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312525217484/d870108d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-217484
- JSON: https://secwatch.observer/filing/0001193125-25-217484.json
- Plain text: https://secwatch.observer/filing/0001193125-25-217484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.